NextCure Q2 net loss narrows on lower expenses
NXTC•Outlook
- NextCure expects merger with Avere Therapeutics to close in the second half of 2026
- Company is preserving capital and reducing expenses in support of merger completion
- NextCure is seeking to preserve value in legacy clinical and pre-clinical assets
Overview
- U.S. cancer drug developer's Q2 net loss narrowed yr/yr on lower R&D and admin costs
- Company announced proposed merger with Avere Therapeutics, expected to close in H2 2026
- NextCure advanced restructuring to cut costs and preserve capital ahead of merger
Key Details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Net Loss | $14.89 mln | ||
| Q2 Income from Operations | -$15.09 mln | ||
| Q2 Loss Per Basic Share | $2.80 |
Analyst Coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
- Wall Street's median 12-month price target for NextCure Inc is $17.50, about 233.3% above its August 5 closing price of $5.25
